DNMT3A silencing RASSF1A promotes cardiac fibrosis through upregulation of ERK1/2

Toxicology

Volumn 323, Issue , 2014, Pages 42-50

  Tao, Hui ^a   Yang, Jing Jing ^a   Chen, Ze Wen ^a   Xu, Sheng Song ^a   Zhou, Xiao ^a   Zhan, Hong Ying ^a   Shi, Kai Hu ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Cardiac fibroblasts; Cardiac fibrosis; DNA methyltransferase 3A; Muscle actin; Ras association domain family 1 isoform A; Smooth

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 3A; MITOGEN ACTIVATED PROTEIN KINASE 3; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE FUNCTION; GENE SILENCING; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; RAT; REGULATOR GENE; SIGNAL TRANSDUCTION; UPREGULATION;

CARDIAC FIBROBLASTS; CARDIAC FIBROSIS; DNA METHYLTRANSFERASE 3A; MUSCLE Α-ACTIN; RAS ASSOCIATION DOMAIN FAMILY 1 ISOFORM A; SMOOTH;

ACTINS; ANIMALS; ANIMALS, NEWBORN; AZACITIDINE; CELLS, CULTURED; COLLAGEN TYPE I; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; FIBROBLASTS; FIBROSIS; GENE SILENCING; ISOPROTERENOL; MALE; MAP KINASE SIGNALING SYSTEM; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 84902971042     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.06.006     Document Type: Article

References (29)

1. Arumugam S., Mito S., Thandavarayan R.A., Giridharan V.V., Pitchaimani V., Karuppagounder V., Harima M., Nomoto M., Suzuki K., Watanabe K. Mulberry leaf diet protects against progression of experimental autoimmune myocarditis to dilated cardiomyopathy via modulation of oxidative stress and MAPK-mediated apoptosis. Cardiovasc. Ther. 2013, 31:352-362.
2. Bechtel W., McGoohan S., Zeisberg E.M., Muller G.A., Kalbacher H., Salant D.J., Muller C.A., Kalluri R., Zeisberg M. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat. Med. 2010, 16:544-550.
3. Challen G.A., Sun D., Jeong M., Luo M., Jelinek J., Berg J.S., Bock C., Vasanthakumar A., Gu H., Xi Y., Liang S., Lu Y., Darlington G.J., Meissner A., Issa J.P., Godley L.A., Li W., Goodell M.A. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat. Genet. 2012, 44:23-31.
4. de Haas H.J., Arbustini E., Fuster V., Kramer C.M., Narula J. Molecular imaging of the cardiac extracellular matrix. Circ. Res. 2014, 114:903-915.
5. Driesen R.B., Nagaraju C.K., Abi-Char J., Coenen T., Lijnen P.J., Fagard R.H., Sipido K.R., Petrov V.V. Reversible and irreversible differentiation of cardiac fibroblasts. Cardiovasc. Res. 2014, 101:411-422.
6. Duan C., Liu M., Zhang J., Ma R. RASSF1A: a potential novel therapeutic target against cardiac hypertrophy. Prog. Biophys. Mol. Biol. 2013, 113:284-288.
7. Hewitt K.J., Sanalkumar R., Johnson K.D., Keles S., Bresnick E.H. Epigenetic and genetic mechanisms in red cell biology. Curr. Opin. Hematol. 2014, 21:155-164.
8. Keller T.E., Yi S.V. DNA methylation and evolution of duplicate genes. Proc. Natl. Acad. Sci. U. S. A. 2014.
9. Leask A. Potential therapeutic targets for cardiac fibrosis: TGFbeta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ. Res. 2010, 106:1675-1680.
10. Li L., Fan D., Wang C., Wang J.Y., Cui X.B., Wu D., Zhou Y., Wu L.L. Angiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-beta1 pathways in cardiac fibroblasts. Cardiovasc. Res. 2011, 91:80-89.
11. Li M., Yi X., Ma L., Zhou Y. Hepatocyte growth factor and basic fibroblast growth factor regulate atrial fibrosis in patients with atrial fibrillation and rheumatic heart disease via the mitogen-activated protein kinase signaling pathway. Exp. Ther. Med. 2013, 6:1121-1126.
12. Martinez-Martinez E., Jurado-Lopez R., Valero-Munoz M., Bartolome M.V., Ballesteros S., Luaces M., Briones A.M., Lopez-Andres N., Miana M., Cachofeiro V. Leptin induces cardiac fibrosis through galectin-3, mTOR and oxidative stress: potential role in obesity. J. Hypertens. 2014, 32:1104-1114.
13. Miyoshi T., Nakamura K., Yoshida M., Miura D., Oe H., Akagi S., Sugiyama H., Akazawa K., Yonezawa T., Wada J., Ito H. Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats. Cardiovasc. Diabetol. 2014, 13:43.
14. Nagalingam R.S., Sundaresan N.R., Gupta M.P., Geenen D.L., Solaro R.J., Gupta M. A cardiac-enriched microRNA, miR-378, blocks cardiac hypertrophy by targeting Ras signaling. J. Biol. Chem. 2013, 288:11216-11232.
15. Palii S.S., Van Emburgh B.O., Sankpal U.T., Brown K.D., Robertson K.D. DNA methylation inhibitor 5-aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B. Mol. Cell Biol. 2008, 28:752-771.
16. Pramod S., Shivakumar K. Mechanisms in cardiac fibroblast growth: an obligate role for Skp2 and FOXO3a in ERK1/2 MAPK-dependent regulation of p27kip1. Am. J. Physiol. Heart Circ. Physiol. 2014, 306:H844-H855.
17. Son J.E., Jeong H., Kim H., Kim Y.A., Lee E., Lee H.J., Lee K.W. Pelargonidin attenuates PDGF-BB-induced aortic smooth muscle cell proliferation and migration by direct inhibition of focal adhesion kinase. Biochem. Pharmacol. 2014.
18. Tao H., Shi K.H., Yang J.J., Huang C., Liu L.P., Li J. Epigenetic regulation of cardiac fibrosis. Cell Signal. 2013, 25:1932-1938.
19. Tao H., Shi K.H., Yang J.J., Huang C., Zhan H.Y., Li J. Histone deacetylases in cardiac fibrosis: current perspectives for therapy. Cell Signal. 2014, 26:521-527.
20. Thaler S., Schmidt M., Schad A., Sleeman, JP RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development. Oncogene 2012, 31:4912-4922.
21. Vaid M., Prasad R., Singh T., Jones V., Katiyar S.K. Grape seed proanthocyanidins reactivate silenced tumor suppressor genes in human skin cancer cells by targeting epigenetic regulators. Toxicol. Appl. Pharmacol. 2012, 263:122-130.
22. Valente S., Liu Y., Schnekenburger M., Zwergel C., Cosconati S., Gros C., Tardugno M., Labella D., Florean C., Minden S., Hashimoto H., Chang Y., Zhang X., Kirsch G., Novellino E., Arimondo P.B., Miele E., Ferretti E., Gulino A., Diederich M., Cheng X., Mai A. Selective non-nucleoside inhibitors of human DNA methyltransferases active in cancer including in cancer stem cells. J. Med. Chem. 2014, 57:701-713.
23. Velmurugan G., Venkatesh Babu D.D., Ramasamy S. Prolonged monocrotophos intake induces cardiac oxidative stress and myocardial damage in rats. Toxicology 2013, 307:103-108.
24. Wang H.L., Liu P., Zhou P.Y., Zhang Y. Promoter methylation of the RASSF1A gene may contribute to colorectal cancer susceptibility: a meta-analysis of cohort studies. Ann. Hum. Genet. 2014, 78:208-216.
25. Watson C.J., Collier P., Tea I., Neary R., Watson J.A., Robinson C., Phelan D., Ledwidge M.T., McDonald K.M., McCann A., Sharaf O., Baugh J.A. Hypoxia-induced epigenetic modifications are associated with cardiac tissue fibrosis and the development of a myofibroblast-like phenotype. Hum. Mol. Genet. 2014, 23:2176-2188.
26. Williams S.M., Golden-Mason L., Ferguson B.S., Schuetze K.B., Cavasin M.A., Demos-Davies K., Yeager M.E., Stenmark K.R., McKinsey T.A. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J. Mol. Cell Cardiol. 2014, 67:112-125.
27. Wu H., Coskun V., Tao J., Xie W., Ge W., Yoshikawa K., Li E., Zhang Y., Sun Y.E. Dnmt3a-dependent nonpromoter DNA methylation facilitates transcription of neurogenic genes. Science 2010, 329:444-448.
28. Yang Q., Shao Y., Shi J., Qu Y., Wu K., Dang S., Shi B., Hou P. Concomitant PIK3CA amplification and RASSF1A or PAX6 hypermethylation predict worse survival in gastric cancer. Clin. Biochem. 2014, 47:111-116.
29. Zhang Y., Huang X.R., Wei L.H., Chung A.C., Yu C.M., Lan H.Y. miR-29b as a therapeutic agent for angiotensin II-induced cardiac fibrosis by targeting TGF-beta/Smad3 signaling. Mol. Ther. J. Am. Soc. Gene Ther. 2014, 22:974-985.